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 ABBREVIATIONS 
API Active pharmaceutical ingredient 
AUC Area under curve 
BBB Blood-brain-barrier 
BCS Biopharmaceutical classification system 
CNS Central Nervous System 
CPP Critical Process Parameter 
CQA Critical Quality Attribute 
DoE Design of experiment 
DS Design space 
DSC Differential scanning calorimetry 
DTE Drug targeting efficiency 
EMA European Medicines Agency 
FDA Food and Drug Administration 
FDNCs Freeze-dried nanocapsules 
GI Gastrointestinal tract 
IV Intravenous 
J Flux 
Kp Permeability coefficient 
LAM Lamotrigine 
LC-MS Liquid chromatography-mass spectroscopy 
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MCC Mucociliary clearance 
MEL Meloxicam 
NaHA Sodium hyaluronate 
NCs Nanocapsules 
NP Nasal powder 
PDI Polydispersity index 
PgP P-glycoprotein 
PM Physical Mixture 
PS Particle size 
PVA Polyvinyl alcohol 
PVP Polyvinyl pyrrolidone 
QbD Quality by Design 
QTPP Quality Target Product Profile 
RA Risk assessment 
SEM Scanning Electron Microscopy 
SNES  Simulated nasal electrolyte solution 
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1. INTRODUCTION 
Nasal drug delivery has received remarkable attention in the past few decades, because the 
nose offers a great alternative administration route due to its special anatomy and 
physiological properties. Via nasal application, local, systemic and central nervous system 
effects are also available and despite the fact that the majority of products are for local use 
(e.g. decongestants), an increasing number of products with systemic and CNS effect is on the 
market. The fact that nasal formulations are not just for local therapy, makes them attractive 
in the therapy of CNS diseases (e.g. epilepsy, Parkinson’s disease, Alzheimer’s disease). 
Nasal administration is pain-free, whilst rapid onset of action can be achieved; therefore, 
enhanced patient adherence can be accomplished. 
Most of the APIs used nowadays are in BCS II, which means that these drugs have low 
solubility and high permeability. One of the most popular ways to improve the solubility of 
APIs is particle size reduction, including nanonization. Nanosized drugs can provide higher 
bioavailability due to their smaller particle size and larger specific surface. There are different 
kinds of technologies with which nanosystems can be produced. The two main groups are 
bottom-up and top-down technologies. In the case of the bottom-up technology, micro or 
nanoparticles are built up from dissolved drug molecules, while in the case of the top-down 
approach, the raw material is subsequently broken down. Both approaches were applied in 
this project as NP formulations were produced with a top-down (co-milling) method, while 
NCs were produced with a bottom-up (solvent displacement) technique. 
QbD is a holistic and systematic quality management method, where the development design 
is risk and knowledge-based. The foundation of a QbD-guided development is RA which can 
be initial, updated, or final. Good RA results are essential for designing the researches more 
efficiently and economically in practice, which makes the studies ecologically friendly, time 
and cost-effective. The thesis reports the development and investigation of two nasal 
formulations that contain nanosized lamotrigine in order to use them in the therapy of 
epilepsy as alternative dosage forms of the traditionally applied tablets. 
Time and cost-effectiveness are key elements during the pharmaceutical research and 
development of different formulations. Thus, the development of proper in vitro models is 
exceedingly significant from an economical and ecological aspect. In the case of nasal 
formulations, due to the unique anatomical and physiological properties, many aspects need to 
be considered during the development procedure. One of the most important factors is the 
permeability rate of the product across the membrane, so its accurate detection is particularly 
important during the development. 
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2. AIMS OF THE WORK 
The aim of this PhD work was to research, develop and investigate LAM-containing nasal 
formulations to induce systemic and CNS effect (Figure 1.). Accordingly, the goal was to 
develop nanosized LAM-containing nasal dosage forms, which could be great alternatives to 
marketed tablets in the therapy of epilepsy. The parts of the project were the following: 
I. Literature review of nasal drug delivery, nanosystems, and QbD methodology in order to 
lay the theoretical foundations of the development of QbD-based, nanosized LAM-containing 
nasal formulations, which would be produced with a top-down and a bottom-up method. The 
reason this field was chosen that despite the well-known advantages of the nasally used 
formulations, just a few nasal powders or nasally administered NCs can be found on the 
market. 
II.  QbD based RA for NP delivery, identification, prioritization, and selection of the most 
influencing CQAs, CPPs of NP production with the tools of QbD. Preliminary study of the 
nanosized API containing NP and selection of the most promising additive. Optimization of 
the dry milling process with DoE, which meant the Design Space determination and 
validation of the powder production. 
III.  Micrometric and structural investigation of NP formulation, moreover the implementation 
of in vitro and in vivo investigations, and parallelly the development, adaptation and 
validation of a novel in vitro horizontal permeability method. 
IV.  QbD based RA for LAM encapsulation, which consisted of the identification, 
prioritization, and selection of the most influencing factors using an Ishikawa diagram. 
Development, optimization, and production of LAM containing NCs, which meant the 
determination of formulation components, their ratios and the process parameters. 
V.  Micrometric and structural investigations of NP formulation, and the implementation of in 
vitro and in vivo investigations. 
VI.  Comparison of NC and NP samples, and based on the in vivo performance of formulations 
and finally, make a suggestion which formulation could be used as an innovative delivery 
system in the therapy of epilepsy.  
 
Figure 1. The aims of the PhD work 
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3. LITERATURE BACKGROUND OF THE RESEARCH WORK 
3.1. Biopharmaceutical aspects of nasal drug delivery 
The nasal cavity – as an alternative route of drug administration – became very important in 
the past years. Due to its unique anatomical and physiological properties, the nose can be a 
major, alternative drug administration route and nasal formulations can offer a major 
breakthrough in different therapies [1,2]. The nasal cavity can be divided into two main 
regions: the olfactory and the respiratory region. The mucosa of the respiratory region, which 
takes up ~ 90% of the surface, is responsible for respiration, the regulation of humidity and 
temperature of inhaled air, as well. The remaining ~10 % of the area is the olfactory region 
which is responsible for olfaction. It is located high in the nasal cavity. It overlies the 
cribriform plate that has a bony structure with many pores. These pores allow the neuronal 
bandles from the olfactory region to pass into the CNS. However, it is important to note that 
besides the olfactory nerve, CNS effect can be achieved via the trigeminal nerve [3]. It is 
possible because the neurons from the branches of the trigeminal nerve pass directly through 
the mucosa (Figure 2.) [4–7].  
If taken nasally, APIs can reach their site of action in several ways. Once on the respiratory 
mucosa, they can get directly into the systematic circulation – or if the particle size is 
inappropriate the API can reach the lungs and then the systemic circulation –, which results in 
increased plasma concentration in a short time. This is the so-called nose to blood delivery. 
However, the API cannot stay on the mucus for longer than 15-20 minutes due to the unique 
physiological process of the nose. The so-called MCC renews the nasal mucosa continuously, 
which means that after some time the API gets into the GI tract through the nasopharynx. 
From this part, the API can also be absorbed into the systemic circulation. Once in the 
bloodstream, the drug can reach any part of the body, including the brain tissues. To do this, 
however, it has to pass through the BBB which is the major limiting factor if the aim is to 
reach CNS effect, but these will be detailed later [8–10]. Yellow arrows mark this possible 
route in Figure 2. 
Marked with red arrows in Figure 2. is another possibility. In this case, the API reaches the 
CNS directly through the trigeminal and the olfactory nerves. This can occur because of the 
free nerve endings (mentioned above) and the so called axonal transport which increases the 
drug concentration in the brain tissues [11]. This kind of nose-to-brain delivery can be 
advantageous e.g. in neurological diseases, pain management or brain tumors [12–16]. 
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Figure 2. The possible routes of API in case of nasal administration. 
If drugs are taken nasally, there are many advantages and opportunities due to the unique 
properties of the nose. First of all, local, systemic and CNS effects are available. It can be 
useful if the API undergoes extensive hepato-gastrointestinal metabolism in the GI tract or the 
drug is irritative or decompose in the GI tract. On the other hand, if there is no or limited 
metabolism, lower doses are sufficient to reach the therapeutic level, thus, GI and other side 
effects become reduced [7]. Another advantage is that the drug administration is painless, and 
sterility is not required. Moreover, the nasal mucosa is highly vascularized and has a large 
surface, which means that the surface of an average human nasal mucosa is approximately 
200 cm2. These properties provide a great opportunity for high permeability and rapid drug 
absorption that leads to a rapid onset of action [17–19]. 
In spite of the high potential, nasal drug delivery has some obvious drawbacks. Nasal 
formulations cannot be used for a longer period as they may damage the nasal mucosa. The 
above mentioned MCC limits the residence time on the mucosa and the BBB limits the access 
to the CNS as particles over ~300 Da are not able to get into the brain tissues. Lipophilicity 
and surface charge are also critical because hydrophilic and charged particles cannot pass the 
BBB. Further limiting factors are nasal enzymatic degradation, limited nasal volume, PgP 
efflux transporters, pathological changes (e.g. runny nose, polyps). These can worsen the 
efficiency of nasal administration [4,20]. 
3.1.1. Nasal products on the market 
Although it has been discovered for centuries that nasal formulations can be used in some 
illnesses, their main application was limited to local diseases until the past one or two 
decades. Accordingly, most of the marketed products are solution-based drops or sprays. The 
reason is that these formulations are safe, easy-to-use and cheap, the dosage is uniform and 
they have been used for decades, so people have got used to them [21]. On the Hungarian 
market, there are 124 marketed nasal products (8 medical products, 116 medications) 
5 
including 113 liquid sprays or drops, 6 ointments, and just 1 powder formulation. This means 
that 94.4 % of the formulations are drops or sprays (Figure 3.). 
 
Figure 3. The distribution of nasal products on the Hungarian market [22] 
Though the most marketed products have localized effect and used mainly in rhinitis or 
allergic diseases, this tendency has changed a bit as the application of nasal formulations has 
extended. Besides the well-known products, there are formulations for the treatment of pain 
management, diabetes insipidus, migraine, hormone-dependent prostate carcinoma, 
postmenopausal osteoporosis, etc. Moreover, there are researches for the formulation of nasal 
products for Alzheimer’s disease, Parkinson’s disease, epilepsy and many other therapies 
[8,19,23]. 
Epilepsy is a common, neurological disease, which is characterized by recurrent, unexpected 
seizures. These seizures are caused by excessive, synchronous or neuronal activity in the 
brain. One of the biggest challenges is that in spite of the epilepsy treatment approximately 
20–30% of patients experience break-through seizures. In these cases, oral or intravenous 
intervention is really difficult and dangerous, alternative routes of administrations are 
required. There are existing rectal formulations of benzodiazepines, but this administration 
route is understandingly unpopular, so there is a need for both acute and chronic treatment 
using multiple types of formulations [24, 25]. 
Intranasal administration of antiepileptic drugs is a promising possibility due to the previously 
mentioned advantages from which rapid onset of action stands out [26]. Accordingly, there 
have been some efforts for the formulation of lamotrigine or midazolam [27]. Midazolam has 
been extensively investigated in epilepsy and some guidelines recommend it as an alternative 
drug delivery for prompt treatment [28].  
In the past few years, nasal powders have gained considerable attention due to the many 
advantages they possess. On the market, there is a poor number of nasal powders used in the 
therapy of migraine and allergic or vasomotor rhinitis [29,30], but in the next few years, the 
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number of formulations will probably increase. Moreover, the FDA has recently approved a 
new product for the treatment of severe hypoglycemia [31]. 
3.1.2. Nasal powders as potential dosage forms in different therapies 
Dry powder formulations are becoming widespread nowadays (oral powders, dry powder 
inhalations, nasal powders) [32–34]. One of the main reasons for the increasing number of 
formulations is that fewer adjuvants are needed during the formulation process. Thus, they 
offer better physicochemical and microbiological stability than liquid formulations. As a 
result, preservatives are not required and also unexpected incompatibilities rarely occur in 
powder formulations. Their shelf life is longer and transport is much easier, but packaging 
must ensure protection against humidity and light [17, 35]. 
Nasal powders (NPs) are formulated to have favorable physicochemical and microbiological 
qualities and stability. Also, the administration dose can be higher compared to liquid 
formulations as the nasal mucosa can accommodate 15-25 mg of powder per nostril per shot, 
while only a maximum of 200 μl per spray in liquid formulations [36]. Nasal powder shave 
high adhesion ability and, therefore, the residence time can be prolonged, which provides 
better absorption through the nasal mucosa, thus, higher bioavailability [37]. Moreover, the 
administration of appropriate adjuvants can slow MCC [38]. As we have discussed before, 
with nasal powders, rapid onset of action can be reached that can be extremely advantageous 
in cases, when rapid intervention is essential (e.g. migraine, pain management) [39]. 
The quality recommendations and quality requirements concerning NPs are included in 
international regulations and guidelines discussing the nasal and inhalational products. From a 
regulatory point of view, nasal products as powerful drug delivery systems are special 
because their design, development, and optimization should be parallel with those of the 
delivery device (e.g., NP inhaler, NP sprayer, NP insufflators) to assure proper dosing. For 
dry powders, the related European Medicines Agency (EMA) and US Food and Drug 
Administration (FDA) guidelines recommend special attention to and critical thinking about 
the following: 1) drug substance specifications, such as particle size (in related literature, it is 
recommended to be around 40 μm), particle size distribution, crystalline form, shape and 
crystallinity which could be critical for product and aerodynamic performance; 2) excipient 
specifications and 3) testing of humidity and temperature sensitivity [40–43].  
3.1.3. Formulation aspects of nasal dosage forms 
In order to achieve a systemic or CNS effect, intranasal formulations usually contain different 
additives to ensure the appropriate viscosity [44], pH (in compliance with the pH of the nasal 
cavity), better mucoadhesion, longer residence time [45], higher permeability rate and often 
[46], controlled release of the API. Due to the MCC in the nasal cavity, the formulation of 
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viscous and mucoadhesive products is needed to reach prolonged contact time with the nasal 
mucosa, thus, enhancing the delivery of the drugs [47] and making therapies more efficient. 
The range and use of applied excipients are wide. To increase the viscosity (cellulose 
derivates) and the mucoadhesive strength (carbomers, chitosans, lectins, thiomers, alginate 
poly(ethylene glycol acrylate) or Poloxamer) of the intranasal formulation, many additives 
can be used [48,49]. Sodium hyaluronate (HA) is one of the most important and most 
commonly used mucoadhesive and biocompatible agent. This anionic, natural polysaccharide 
owns great mucoadhesive capacity [50], low immunogenicity and high biocompatibility [51]. 
Moreover, it can improve the absorption of drugs and proteins via mucosal tissues [52]. 
However, to ensure controlled drug delivery, other polymers (PVA, PVP, α-cyclodextrins) are 
also applied [53]. 
The solubility of the API, the size and mass of the molecule, the pKa value, the polarity, the 
rate of dissolution and permeability need to be highly considered when formulating nasal 
products [54]. All of the mentioned properties can be improved by size reduction to the micro 
or nano range and, thus, micronization and nanonization could be a great choice in order to 
prepare formulations for poorly water-soluble drugs with increased bioavailability [55, 56]. 
3.1.4. Nasal form investigations 
In addition to the usual investigations, nasal formulations are needed to be tested specifically. 
According to the Pharmacopeia, many properties of the nasal formulations should be 
investigated such as uniformity of mass, API content or particle size. It is also desirable to 
perform other tests specific to the particular formulation [57, 58]. 
In the case of the product, permeability is one of the most influencing factors of quality. 
Therefore, an accurate, easy, well-reproducible and robust technique is extremely important 
during the development of a nasal product [59]. There are many ways to measure permeability 
and these are available on the market, but in our opinion, a more complex method could be 
developed. Most of the devices used are vertical, such as the commonly used Franz cell, but 
there are some devices with a horizontal layout. In all devices, there is a donor and an 
acceptor phase, which is separated by a semipermeable membrane in order to model the 
physiological conditions of the human body [60]. It is advantageous if the diffusion cells can 
be tempered and continuous magnetic stirring is possible. Moreover, it is also desirable to use 
an inline technology, which means that the measurement can be screened in real-time. It is 
useful because in case of an adverse event (e.g. membrane rupture), the investigation can be 
interrupted, so it is not detected at the end of the investigation. This makes this approach time 
and cost effective over offline techniques. Other advantages of inline measurements include 
easy implementation, reproducibility, independence from the implementor, and no need for 
constant supervision. 
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As the device plays a quite important role in the efficacy of nasal administration, its selection 
and investigation are essential during the development process. Device type depends on the 
dosage form, the number of doses, the indication of the API and many other parameters. The 
key factors, which are always investigated, are robustness, dose uniformity and packaging 
integrity, but several other properties are also investigated before approval [61].  
3.2. General review and engineering possibilities of nanoparticles 
Nanonization is an up-to-date research topic in almost every scientific field. In the 
pharmaceutical sector, particle size reduction to the micro or nano range is a promising way to 
improve the dissolution rate of poorly water-soluble drugs [62–64]. The size of nanoparticles 
is in the range of 1-1000 nm [65]. Nanonization can provide decreased particle size, and 
parallelly, increased specific surface area, which leads to an increased contact surface for API 
particles (Figure 4.) [66–69]. Thus, nanonization can result in improved drug dissolution rate 
[70] and pharmacokinetics [71], while the appearance and intensity of systemic side effects 
might also decrease [72,73]. All in all, nanonization, in some cases, can lead to improved 
bioavailability, which is still highly desirable, which can result in a breakthrough in drug 
administration via alternative routes [74]. The possible, but not sufficiently proven drawback 
of nanonization is the so-called nanotoxicity, which is the harmful accumulation of 
nanoparticles in tissues and organs [75]. 
 
Figure 4. Due to the smaller particle size and larger specific surface, nanoparticles have higher contact 
surface with membranes [76] 
Several methods exist for the preparation of nanoparticles, which can be divided into two 
main groups: top-down and bottom-up processes [76]. Top-down methods (such as co-
grinding with additives) produce micro or nanoparticles by using mechanical stress. These 
technologies are environmentally and economically advantageous because they are organic 
solvent-free, simple and well reproducible. In this case, nanoparticles are produced by 
grinding the drug together with additives which are responsible for the stability and 
maintenance of the uniqueness of the particles [77, 78]. Nanoparticles are controlled by 
adhesive forces and, if the particles are not stabilized, they may coagulate because of the high 
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particle mobility. Different additives are used to stabilize these particles: polysorbate, 
hydroxypropyl methylcellulose, Poloxamer, PVP, etc. [79]. PVA is frequently used as a 
stabilizer, coating the particles and promoting their separation from each other. 
Bottom-up technologies (e.g. nanoprecipitation, API encapsulation) are also used for 
producing nanoparticles. These techniques involve a poorly water-soluble drug, a suitable 
solvent, and a miscible anti-solvent. The process is based on the principle of transferring the 
API from the molecular state to a precipitated state under continuous stirring, which leads to 
the growth of nanoparticles. The solvents are needed to be completely miscible and suitable 
for the formation of nanosuspensions, drug nanocrystals, or nanodispersions. The advantages 
of these methods are that they are robust and well-reproducible. Possible disadvantages are 
the presence of possibly toxic organic solvents, the separation of nanoparticles takes time and 
experienced implementors are needed to execute the preparation method, while just really low 
drug concentration is available [76]. 
In the last decade, the encapsulation of APIs, which is a kind of bottom-up process, has 
become increasingly important due to its advantages over traditional technological methods 
for solubilization (e.g. solid dispersions, amorphization). The additives which can be used 
during the formulation are diverse, but liquid oils and surfactants are the most commonly used 
adjuvants. The core-shell nanosystems can also be covered with many polymers in order to 
protect the oily, liquid core. One of the most commonly used polymer is chitosan, which can 
increase the adhesion property of NCs and extend their residence time on the mucosal surface 
[80, 81]. 
3.2.1. Powders containing nanosized API 
As it has been previously discussed, nanosized API-containing powders for nasal drug 
administration have many advantages that can be combined. With nanoparticles, a smaller 
dose could be enough to reach the therapeutic level, and the increased specific particle surface 
can be exploitable on the large nasal mucosal surface. Moreover, if it is desirable, higher 
doses can be administered via powder formulations, and they can offer longer residence time 
and better adhesion than liquid formulations. Also, the small particles can enter the systematic 
circulation or CNS rapidly – it is called a prompt effect in case of nanoparticles – so the rapid 
onset of action can be even faster with nanoparticles. 
However, nanosized APIs cannot be administered on their own. Powder products need to fall 
into the particle size range 10–45 μm. Below this size, the powder can be inhaled into the 
lungs, while over this size, the powder cannot reach the nasal mucosa. This means that a 
proper carrier is needed during the formulation that ensures particle size, good flow 
properties, and prevents the aggregation of nanoparticles during the storage. This last criterion 
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is extremely important because aggregation can influence the efficiency of the formulation in 
the wrong way [80, 81]. 
3.2.2. Nanocapsules as novel therapeutical nanosystems 
Some nanocarriers can improve the solubility of hydrophobic drugs and thereby enhance their 
bioavailability [84, 85]. NCs, which consist of an oily core and a biodegradable polymer shell, 
can be produced with bottom-up technologies [86]. This structure can protect the APIs from 
the physiological environment (e.g. pH and enzymatic degradation) and enhance their 
permeability through biological barriers [87–89]. Further advantages are that the NCs can 
reduce drug toxicity and increase their stability; they can facilitate the API transport across 
mucosal surfaces; and they can provide controlled release. Solid and liquid state NCs have 
been developed for different administration routes. Among these routes, the oral and the 
parenteral routes are the most researched, but there have been some efforts to prepare dermal, 
ocular, or nasal formulations [90,91]. 
3.3. Quality by Design 
QbD is a holistic and systematic quality management method, where the development design 
is risk and knowledge-based; thus, the experiments in practice can be planned more efficiently 
even in the development of nasal formulations [92]. In a QbD-based development, the first 
step is the prior definition of the QTPP (essential parameters from the point of view of the 
patient and the clinical setting). The next step is the selection of the parameters that influence 
the QTPP critically. These are the CQAs related to the materials and products, and the CPPs 
related to the selected production method. The key element of a QbD-guided development is 
RA, which can be initial, updated or final. Good RA results are essential for designing the 
studies in practice. RA-based development and screening could be more effective and can be 
used successfully even in the early development of pharmaceutical products [93–97]. 
With QbD, the experiments can be planned more economically and efficiently. DoE, a tool of 
the QbD paradigm, is a systematic approach [98]. It allows the finding of optimal product 
and/or process parameters and usually provides a larger amount of information from fewer 
experimental runs. It is available by varying the factors and simultaneously evaluating the 
effect of multiple variables. DoE is also useful for identifying the individual and interacting 
factors [99]. Using the response surface, the methodology may lead to the development of DS, 
which assures the quality of the desired product and can be defined for both the formulation 
and the process parameters [100]. 
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4. MATERIALS AND METHODS 
4.1. Materials 
LAM, poorly water-soluble (0.17 mg/mL at 25 °C) second-generation antiepileptic drug of 
the phenyltriazine class [101,102] was purchased from Teva Ltd. (Budapest, Hungary). The 
milling additives, polyvinyl pirrolidon (PVP) (Mw=24000) and polyvinyl alcohol (PVA) 
(Mw=27,000), water-soluble synthetic polymer were supplied by ISP Customer Service 
GmBH (Cologne, Germany). Sodium hyaluronate (NaHA) polymer was purchased from 
Gedeon Richter Ltd. (Budapest, Hungary). 
The NC additives: glyceryl monooleate (Type 40) (Peceol®) and diethylene glycol monoethyl 
ether (Transcutol HP®) were a kind gift from Gattefossé (St. Preist, France). Polyoxyethylene 
(40) monostearate (PEG-stearate 40) was purchased from Croda (East Yorkshire, United 
Kingdom). Chitosan hydrochloride salt was obtained from HMC+ (Halle, Germany). 
Mannitol was obtained from Sigma-Aldrich (New York, USA). Table 1. and Table 2. show 
the properties of the applied materials. 
Table 1. Features of the active agent 
 LAM 
Chemical structure 
 
Chemical name 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine 
Physical properties white powder, poor water-solubility 
Mechanism of action inhibiting voltage-sensitive sodium channels thereby stabilizing 
neuronal membranes and consequently modulating presynaptic 
transmitter release of excitatory amino acids such as glutamate 
and aspartate 
Applications epilepsy (partial seizures, primary and secondary tonic-clonic 
seizures, and seizures associated with Lennox-Gastaut 
syndrome), bipolar disorder (maniac period) 
 
The APIs used during the development of in vitro permeability method was levodopa (LEV) 
(L-3,4-dihydroxyphenylalanine) which was obtained from Hungaropharma Ltd.(Hungary) and 
meloxicam (MEL) (4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-benzothiazine-3-
carboxamide-1,1-dioxide) which was obtained from EGIS Ltd. (Budapest, Hungary). 
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Table 2. Properties of additives 
 Chemical structure 
Physical 
properties 
Application 
PVP 
 
white powder carrier 
PVA 
 
yellow or 
white powder 
or crystals 
carrier, 
adhesion 
enhancer 
NaHA 
 
white powder 
mucoadhesive 
agent 
Glyceryl 
monooleate 
(Type 40) 
(Peceol
®
)  
easily flowing 
liquid 
liquid oil 
Diethylene 
glycol 
monoethyl 
ether 
(Transcutol 
HP
®
)  
easily flowing 
liquid 
surfactant 
Polyoxyetylene 
(40) 
monostearate 
(PEG-stearate 
40) 
 
colorless or 
whitish solid 
material 
surface modifier 
Chitosan 
hydrochloride 
 
white powder shell component 
Mannitol 
 
white powder cryoprotectant 
4.2. Methods 
4.2.1. Identification of factors affecting product quality 
As part of the QbD methodology, an Ishikawa diagram was set up to identify a knowledge 
space of the nasal powder and NC formulations. With the Ishikawa diagram, the identification 
and systematization of influencing factors were carried out. The factors with the highest 
influence were chosen and varied. 
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4.2.2. Initial RA of nasal powder 
To perform the QbD-based initial RA, the first step was the determination of the QTPP of the 
aimed product. After that, the CQAs and the CPPs of the selected production method were 
identified. To this identification, a knowledge space development was executed as part of the 
QbD methodology and an Ishikawa diagram was set up. For performing the RA, the 
LeanQbD® software (QbD Works LLC, Fremont, CA, USA) was used as a technical tool. The 
first step of RA was to carry out an interdependence rating among the QTPP and CQAs and 
also among the CQAs and CPPs. A three-level scale was used to describe the relationship 
between the parameters. Accordingly, the interaction between the elements was described as 
“high” (H), “medium” (M) or “low” (L). The dynamism of this interdependence rating is 
presented in tables generated by the software. This was followed by the probability rating 
step, in which CPPs were estimated and categorized on a 10-point scale. Finally, Pareto charts 
were generated by the software, presenting the numeric data and the ranking of the CQAs and 
CPPs. 
4.2.3. Experimental Design of nasal powders 
To determine the optimal process parameters a full factorial design was set up with 3 factors 
on 3 levels, using MODDE 11.1 software (Umetrics, Sweden). The software generated 27 
experimental runs as well as 3 center points used to calculate the degrees of freedom, the 
reproducibility. The milling time (X1), milling speed (X2) and the PVA:LAM ratio (X3) were 
selected as input variables indicated by RA. To characterize the powders, the following 
responses were chosen according to RA: average particle size (Y1) and its standard deviation 
(Y2), the percentage of dissolved LAM from the samples after 5 (Y3) and 10 minutes (Y4). 
The Factor variation levels and the acceptable ranges of CQAs were chosen based on the RA, 
prior knowledge and relevant literature. The data fitting and the determination of the 
statistical parameters were done using the same DoE software. The effects of the independent 
variables were modeled using the Partial Least Squares method. ANOVA test was applied to 
evaluate the significance of models (p < 0.05). Individual response parameters were evaluated 
using F-test.  
For regression analysis, the goodness of fit, the capacity of prediction, model validity, and 
reproducibility were considered. The goodness of fit of a model is given by the value of R2 
and represents the variation of the response explained by the model. Q2 represents the 
goodness of prediction and reveals how well the model can predict new experiments [100].  
Response contour plots were generated to allow illustrate the relationship between the 
different experimental variables and the responses. Finally, based on experimental results, the 
DS was determined. 
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4.2.4 Dry milling method for nasal powder production 
PVP, PVA, and NaHA were used for sample preparation as additives to maintain the stability 
and individuality of nanosized LAM particles. Figure 5. shows the process of sample 
preparation, where given amount of LAM and additives (1:1, 1:2 and 2:1 ratios) were placed 
in a Turbula mixer (Turbula System Schatz; Willy A. Bachofen AG Maschinenfabrik, Basel, 
Switzerland) using 60 rpm for 10 minutes; thus, interactive PMs were prepared. 
 
Figure 5. The sample preparation protocol of milled samples and PMs [82] 
During the preliminary experiments, the effects of three API:additive ratios (1:1, 1:2 and 2:1), 
milling time (2, 4 and 6 hours) and speed (200, 400 and 600 rpm) were investigated. The 
optimal parameters of dry milling were selected on the basis of these experiments and can be 
found in Table 3. The samples are marked with „R”. 
Table 3. Applied ratios (w/w) and milling parameters for nasal powder formulation  
 Ratio Milling time (h) Milling speed (rpm) 
R_LAM_PVP 
1:1 2 400 R_LAM-PVA 
R_LAM-NaHA 
After mixing, the PM samples were placed into a planetary ball mill (Retsch PM 100; Retsch, 
Neuhausen, Germany), where they were milled for 2 hours at 400 rpm in a 50 mL capacity 
milling chamber. For milling, 10 steel balls (diameter 10 mm, the weight of each ball 4.02 g) 
were used to get the co-milled samples. As a comparison, PM samples were used. In those 
cases, the additives were milled using the same parameters, while after they were mixed with 
LAM in the above mentioned Turbula mixer using 60 rpm for 10 minutes. 
In the case of the DS validated sample, which is called nanoLAMpowder, PVA was used as 
an additive during the sample preparation process to maintain the stability and non-aggregated 
property form of LAM particles. NanoLAMpowder was produced as follows: 0.8 g PVA and 
1 g LAM were mixed in a Turbula mixer (Turbula System Schatz; Willy A. Bachofen AG 
Maschinenfabrik, Basel, Switzerland) using 60 rpm for 10 min. After mixing, the sample was 
placed into a planetary ball mill (Retsch PM 100; Retsch, Neuhausen, Germany) and milled in 
a 50 mL capacity milling chamber for 1.5 h on 400 rpm with 10 steel balls (diameter 10 mm, 
the weight of each ball 4.02 g). In the case of PM, PVA was milled for 1.5 h on 400 rpm and 
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then – according to our previous experiments – it was mixed with non-milled LAM using the 
same Turbula mixer for 10 mins on 60 rpm. 
4.2.5. Nanocapsule production 
Solvent displacement method for nanocapsule production 
The NCs were prepared by a solvent displacement method, whose composition (Table 4.) was 
determined after preliminary experiments. The organic phase was first prepared by adding 
100 μL of LAM solution (100 mg/mL DMSO solution), 41.7-41.7 μL Peceol® and 
Transcutol® to 816.6 μL PEG-stearate 40 solution (5.33 mg/mL ethanol solution). Then, this 
solution was poured over 2 mL of ultrapure water upon continuous magnetic stirring. After 
10 minutes, 2 mL of chitosan solution (1 mg/mL) was added upon magnetic stirring, leading 
to the spontaneous formation of the NCs.  
Table 4. The compositition of the NC formulation 
LAM solution(100 mg/mL) (μL) 100 
+ 2 mL MilliQ 
water 
+ 2 mL 1 mg/mL 
Chitosan solution after 
10 mins 
Peceol
® (μL) 41.7 
Transcutol
®(μL) 41.7 
PEG-stearate 40 solution 
(5.33 mg/mL EtOH solution) 
ad 1 mL 
After 10 additional minutes of stirring, the NCs were isolated and concentrated to a final 
theoretical chitosan concentration of 1 mg/mL by centrifugation (Hettich Universal 32 R; 
Tuttlingen, Germany) at 33000xg for 33 min at 15 °C. In parallel, control blank NCs, without 
LAM were prepared using the same method. 
Freeze-drying method for solid-phase nanocapsule production 
The freeze-drying was performed in Scanvac CoolSafe 100-9 Pro type equipment (LaboGene 
ApS, Lynge, Denmark) equipped with a 3-shelf sample holder unit, recessed into the drying 
chamber. The prepared NCs were lyophilized with 5% mannitol. The process was controlled 
by a computer program (Scanlaf CTS16a02), the temperature and pressure values were 
recorded continuously. In the first period of the freeze-drying, the chamber was cooled from 
room temperature to -25 °C. At this time the vacuum was turned on (p=0,013 mBar). Then the 
samples were kept under these conditions for 12 hours, while after during the secondary 
drying the temperature was raised up to +25 °C. temperature. The secondary drying lasted for 
4 hours. Thereafter, the freeze-dried NCs (FDNCs) came up. Figure 6. illustrates the process 
of the NC preparation. 
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Figure 6. The process of NC and FDNC preparation 
4.2.6. Micrometric investigation methods 
Determination of particle size of NP formulation 
The particle size of the microparticles was characterized by using Leica Image Processing and 
Analysis System device (Leica Q500MC; Leica Microsystems, Wetzlar, Germany). The test 
parameters of 300 particles were their length, width, area, and district/convex perimeter. 
The particle size of the LAM nanoparticles – the particles were on the surface of the polymer 
microparticles – were investigated by SEM pictures (Hitachi S4700; Hitachi Ltd., Tokyo, 
Japan) at 10 kV. The distribution of LAM particle diameter was obtained by analyzing SEM 
images with the ImageJ software (1.50i; Java 1.6.0_20 [32-bit]; Windows NT) environment 
using approximately 500 particles. 
Particle size, particle size distribution and surface charge characterization of NCs 
The particle size and polydispersity index of the NCs were determined by photon correlation 
spectroscopy (PCS) (Zetasizer NanoZS®, Malvern Instruments; Malvern, United Kingdom). 
In the case of surface charge, zeta potential (ZP) measurements were done by laser Doppler 
anemometry (LDA) using the same equipment. All the measurements were performed at 
25 °C with a detection angle of 173º in distilled water unless otherwise indicated. The freeze-
dried NCs were investigated with the same instrument after redispersion with MilliQ water. 
The FDNCs samples were investigated after resuspension in MilliQ water. 
Image analysis (SEM) 
The morphology of particles was investigated by SEM (Hitachi S4700; Hitachi Ltd., Tokyo, 
Japan) at 10 kV. The samples were gold–palladium-coated (90 s) with a sputter coater (Bio- 
Rad SC502; VG Microtech, Uckfield, UK) using an electric potential of 2.0 kV at 10 mA for 
10 min. The air pressure was 1.3–13.0 mPa.  
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4.2.7. Structural investigations 
Differential scanning calorimetry (DSC) 
The thermal response of each product was measured using a differential scanning calorimeter 
(Mettler Toledo TG 821e DSC; Mettler Inc., Schwerzenbach, Switzerland). About 3–5 mg of 
powder was precisely weighed into DSC sample pans, which were hermetically sealed, and 
the lid was pierced. Each sample was measured in the temperature interval of 25–230 °C at a 
heating rate of 5 °C/min and under a constant argon flow of 150 mL/min. Data analysis was 
performed using the STARe software (Mettler Toledo; Mettler Inc., Schwerzenbach, 
Switzerland). The crystallinity index was calculated based on the normalized integral values. 
PM samples were regarded as 100%. 
X-ray powder diffraction (XRPD) 
The XRPD measurement was carried out with a BRUKER D8 advance X-ray powder 
diffractometer (Bruker AXS GmbH, Karlsruhe, Germany) with Cu⋅K λI radiation (λ=1.5406 
Å) and a VÅNTEC-1 detector (Bruker AXS GmbH, Karlsruhe, Germany). The powder 
samples were loaded in contact with a plane quartz glass sample slide with an etched square 
and measured. Samples were scanned at 40 kV and 40 mA. The angular range was 3–40° 2θ, 
at a step time of 0.1 seconds and a step size of 0.007°. All manipulations, including Kα2 
stripping, background removal and smoothing of the area under the peaks of the 
diffractograms, were performed using the DIFFRACplus EVA software. The crystallinity 
index (Xc) values were calculated based on the following formula (Equation 1.), where A 
marks the area under the whole curve: 
 
PM samples were regarded as 100%. 
4.2.8. In vitro studies 
Encapsulation efficacy (EE) and drug loading (DL) of NCs 
After centrifugation, the supernatant was analyzed for the amount of drug present with a UV 
spectrophotometer (SynergyTM H1 Microplate Reader, BioTek Instruments, Inc.) at λmax of 
307 nm after suitable dilution. EE% was calculated by the following equation (Equation 2.): 
%EE=((W1-W2)/W1)*100 
Loading capacity (percentage drug loading [%DL]) was calculated by Equation 3.: 
%DL=((W1-W2)/(W1-W2+ Wlipid)*100 
where, W1, W2, and Wlipid are the weight of drug added to the formulation, the analyzed 
weight of the drug in the supernatant, and the weight of the lipid added to the formulation, 
respectively. 
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In vitro release study of nasal powders 
The modified paddle method (USP dissolution apparatus, type II; Pharma Test, Hainburg, 
Germany) was used to examine the dissolution rate of the samples and determine their drug 
release profile. The tests were carried out under nasal conditions for temperature and pH. 
100 mL phosphate-buffered saline solution (PBS of pH 5.60 at 30 °C) was used as a medium, 
in which 108 mg of the samples were tested in case of nasal powders. The paddle was rotated 
at 50 rpm, and the sampling points were at 5 min, 10 min, 15 min, 30 min, and 60 min. In the 
beginning, the sampling point was more frequent, because the beginning of the investigation 
is more important as the mucociliary clearance renews the mucus every 15 min. The 
following sampling points offered extra information about the dissolution behavior of LAM. 
After filtration, the drug content of the aliquots was determined using spectrophotometry 
(Unicam UV/VIS Spectrophotometer, Cambridge, UK) at 307 nm. The tests were carried out 
in triplicates. 
In vitro release study of NCs 
The modified paddle method (USP dissolution apparatus, type II; Pharma Test, Hainburg, 
Germany) was used to examine the dissolution rate of NCs and determine the drug release 
profile from the samples. To model the nasal pH and temperature conditions, the medium was 
9 mL phosphate-buffered saline (PBS) adjusted to pH 5.60. Samples with 1,65 mg LAM were 
tested in this medium at 30 °C with paddle stirring at 50 rpm. The sampling points were at 
5 min, 10 min, 15 min, 30 min, 45 min, and 60 min. The first data points were considered the 
most important as the mucociliary clearance renews the mucus every 15 min. The following 
data points offered additional information about the dissolution behavior of LAM. The 
samples were investigated with an RP-HPLC-DAD system. The RP-HPLC-DAD consisted of 
an Agilent 1200 Series chromatograph and a DAD detector. The stationary phase was a 
Kinetex® C18 colonna (150 mm x 4,6 mm, particle size: 5 μm, pore diameter size: 100 Å). The 
separation was isocratic, the composition of the mobile phase was 0,01 M phosphate buffer 
(pH= 6,7 ±0,1): methanol:acetonitrile = 50:20:30 (v/v). The analytical column was tempered 
for 25 °C and the measurements lasted 10 mins. The flow rate was 0.75 mL/min, and 10 µL of 
the sample was injected into the flowing fluid, measured at 307 nm. The equation for the 
calibration line was y = 12,335x - 3,488 (R2=1). The equation was valid in the range of 10-
150 μg/mL. The tests were carried out in triplicates. 
4.2.8.1. Development of in vitro permeability investigation method 
Horizontal diffusion studies 
A horizontal diffusion device (Side-Bi-Side™ Crown Glass, USA) was used for the 
investigation of NPs and the tests were carried out under nasal conditions. Regenerated 
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cellulose membrane (Whatman™) with 0.45 μm pore diameter was soaked in IPM, and the 
donor phase was tempered to 30 °C at pH 5.6. The acceptor phase was pH 7.4, and the content 
of the diffused drug was measured spectrophotometrically at 307 nm (Unicam UV/Vis 
Spectrophotometer, Cambridge, UK). 
The execution of diffusion measurements 
Then we aimed to develop the above-mentioned method, the same device (Figure 7.) was 
investigated and used to optimize a method proper for API-investigations comprising 
different logP values. The factors listed on the Ishikawa diagram influence the efficiency of in 
vitro membrane diffusion in different extent. The modification consisted of the change in the 
volume of the chambers (from 3 mL to 9 mL), the arrangement of the space for the magnetic 
stirrers, the design of probe input for real-time analysis, membrane surface with a small area. 
This device consists of two chambers: a donor and an acceptor phase with a horizontal 
orientation. Our donor and acceptor phases were 9 mL. The volume of the nasal cavity is 15-
20 mL which is divided by the nasal septum into fossae, therefore 9 mL was the ideal choice 
to model the absorption in the nasal fossa. The temperature was set at 30 °C suiting the 
average temperature of the human nose. The rotational speed of magnetic stirrers was around 
100 rpm.  
 
Figure 7. The setup of the horizontal device used for in vitro modeling of the penetration of the nasal 
powders 
Three types of membrane (Metricel®, Isopore™ or Whatman™) were chosen and isopropyl 
myristate was used as an impregnation agent to imitate the hydrophobic property of the wall 
of the nasal epithelial cells, reference was a PBS (pH=7.4). 10±0.50 mg powder of APIs 
(MEL, LAM, LEV) was weighted and the results were corrected depending on the actual 
weight because the human nose can accommodate around 10-25 mg powder per nostril per 
shot [21]. The penetration extent (PAPI, µg/cm2) can be used in the case of nasal formulations 
to describe the extent of diffusion. In spite of that, thanks to the mucociliary clearance, the 
residence time of the nasal formulations are around 15 min on the nasal mucosa, the 
measurements lasted for 60 min so that the kinetics could be better characterized. 
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The diffusion surface was 0.785 cm2. The area of nasal mucosa in the human body is around 
200 times larger: 160 cm2 [103], therefore presumably multiple times more API would be  
supposed to be penetrated (Equation 4.) in vivo than in the horizontal device. 
 
The MEL was quantified at 366 nm, LAM: at 307 nm, LEV: 281 nm. 
Offline spectrophotometric measurements 
At determined moments (5, 10, 15, 30, 45 and 60 min), 2 mL samples were taken from the 
acceptor phase and the volume was made up to 10 mL, therefore the acceptor phase was 
diluted after every occasion. The dissolved drug amount was determined 
spectrophotometrically (PerkinElmer, Lambda 20 spectrophotometer, Dreieich, Germany). 
The path length was 1 cm. Flux (J) and permeability coefficient (Kp) values were calculated 
according to the following formulas (Equation 5. and 6.): 
J=m/(A*t)    Kp= J/cd 
where m is the amount of diffused LAM, A is the surface of the membrane, t is the time and 
cd is the concentration of LAM in the donor phase. 
Inline measurements with a probe connected with an optical fiber to a spectrophotometer 
An AvaLight DH-S-BAL spectrophotometer (AVANTES, Apeldoorn, Netherlands) was 
connected to an AvaSpec-2048L transmission immersion probe (AVANTES, Apeldoorn, 
Netherlands) with optical fiber to quantify the amount of the API. The path length was 1 cm. 
The limiting factor of inline measurements can be that no dilution occurs in the acceptor 
phase during the measurements which could model the dilution happening in the blood by 
transferring the API from the direct environment of the nose [104]. 
Application of modified permeability investigation method 
As for the LAM measurements, the arithmetic mean of the Metricel® membrane was a bit 
lower compared to Whatman™, the higher extent of penetration was in favor of the use of 
Whatman™ in inline measurements when the impregnation agent was IPM. In the case of 
IPM impregnation, the inline measurements were more precise than the offline ones, 
therefore, they are suggested. This means that the previously used method and parameters 
were the most suitable for LAM and, therefore, the NCs were measured with the same method 
like the NPs were, but with AvaLight DH-S-BAL spectrophotometer (AVANTES, 
Apeldoorn, Netherlands) connected to an AvaSpec-2048L transmission immersion probe 
(AVANTES, Apeldoorn, Netherlands) with optical fiber to quantify the amount of API. The 
path length was 1 cm. The NPs were remeasured with the inline method and there was no 
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significant difference in the results, so we decided to use the original data, but we were able to 
set up a new method, which is easy to implement, more accurate, more reproducible, which 
made our experiments more simple and more effective. 
4.2.9. In vivo studies 
Intranasal administration, blood sample collection, and brain removal 
The nanoLAMpowder and also the PM contained 0.555 mg, while the NC formulation 
contained 0.066 mg LAM and the FDNCs formulation contained 0.039 mg LAM. The doses 
were the maximums that a rat nostril can tolerate and we were able to administer. The 
formulations were administered into the right nostril of 160–180 g male Sprague–Dawley rats 
(n=4) with a small spatula or pipette. The administration was carried out under isoflurane 
short anesthesia. As a control, IV injections of LAM solutions (IV LAM), which contained 
0.555 mg of API were given to rats (n=4). At predetermined time points (3, 6, 10, 20, 40 and 
60 minutes) after LAM administration, blood samples were collected by cardiac puncture into 
heparinized tubes under deep isoflurane anesthesia. Then the animals were sacrificed by 
decapitation, and brain tissues were quickly removed, rinsed in ice-cold PBS, divided into left 
and right hemispheres, weighed, and stored at -80 °C until assayed. The experiments were 
performed according to the EU Directive 2010/63/EU for animal experiments and were 
approved by the Hungarian Ethical Committee for Animal Research (permission number: 
IV/1247/2017). 
Plasma sample preparation 
To 100 µL of plasma samples 20 µL internal standard solution (0.4 µg/mL, lamotrigine-13C3, 
d3 in methanol-water, 50:50, v/v), 20 µL methanol-water mixture (50:50, v/v) and 100 µL 2M 
sodium hydroxide were pipetted, and the samples were vortexed. For the liquid-liquid 
extraction, 1 mL ethyl acetate was added to each tube and vortexed for 1 min, shaken at room 
temperature for 10 min and left on ice for 5 min. After centrifugation, 300 µL of the 
supernatant was transferred to a 1.5 mL glass vial and evaporated to dryness at room 
temperature using a gentle stream of nitrogen. The samples were resuspended in 50 µL of 
acetonitrile containing formic acid (0.1% v/v) and diluted with 0.1% formic acid to a final 
volume of 400 µL. 20 µL was injected into the LC-MS/MS system for analysis. 
Prior to the extraction of the calibration and quality control samples, 20 µL of a standard 
solution (6.25 ng/mL – 8 µg/mL LAM) was added to LAM-free pooled rat plasma instead of 
a methanol-water mixture. The rest of the sample preparation steps were the same as 
described above. 
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Brain tissue sample preparation 
Brain samples were homogenized in water (4 mL/g wet tissue weight) on ice 2 times for 30 
seconds with an ULTRA-TURRAX blade-type homogenizer (IKA® Works, Inc; Wilmington, 
USA) and for 30 seconds with a BioLogics Model 150VT ultrasonic homogenizer (BioLogics 
Inc, Manassas, USA). The samples thus prepared were stored at -80 °C until use. On the day 
of extraction the samples were thawed, and to 200 µL brain homogenates 20 µL internal 
standard solution (0.5 µg/mL, lamotrigine-13C3, d3 in methanol-water, 50:50, v/v), 20 µL 
methanol-water mixture (50:50, v/v) and 20 µL 20% (w/v) trichloroacetic acid (TCA) were 
added. Samples were vortexed and centrifuged with 10,000 x g at 20 °C for 10 minutes and 
then 100 µL of the supernatant was placed to a new test tube. LAM was extracted after adding 
100 µL 4M sodium hydroxide and 1 mL ethyl acetate, by vortexing for 1 min, shaking at 
room temperature for 10 min and resting on ice for 5 min. After centrifugation, 700 µL of the 
supernatant was transferred to a 1.5 mL glass vial then evaporated to dryness at room 
temperature. The samples were resuspended in 50 µL of acetonitrile containing formic acid 
(0.1% v/v), diluted with 0.1 % formic acid to a final volume of 370 µL and than 20 µL was 
injected into the LC-MS/MS system for analysis. 
Prior to the extraction of the calibration and quality control samples, 20 µL of a standard 
solution (7.8125 ng/mL - 10 µg/mL LAM) was added to the pooled LAM-free rat brain 
homogenate instead of a methanol-water mixture. Further sample preparation steps were the 
same as described above. 
LC-MS/MS 
The liquid chromatographic separation was performed on an Agilent 1100 Series HPLC 
system (Agilent; Santa Clara, USA) using a Kinetex C18 (2.6 µm 100A, 50 x 2.1 mm) 
column (Phenomenex; Torrance, USA). In front of the analytical column, a C18 guard 
column was used. Water (A) and acetonitrile (B) both containing formic acid (0.1% v/v) were 
used as mobile phases. A gradient elution program was used to elute components: gradient 
started at 13% B, increased linearly to 90% B in 3 min, kept at 90% B for 2 min, dropped 
back to 13% B in 0.1 min and kept at 13% B for 2.9 min. The flow rate was set at 300 µL/min 
for the separation and 500 µL/min to wash and equilibrate the column. The autosampler and 
the column were maintained at room temperature. 
Samples were analyzed with an on-line connected Q Exactive Plus quadrupole-orbitrap hybrid 
mass spectrometer (Thermo Fisher Scientific; Waltham, USA) equipped with a heated 
electrospray ion source (HESI). It operated in positive mode with the following conditions: 
capillary temperature 256 °C, S-Lens RF level 50, spray voltage 3.5 kV, sheath gas flow 48, 
sweep gas flow 2 and auxiliary gas flow 11. The automatic gain control (AGC) setting was 
defined as 2 × 105 charges and the maximum injection time was set to 100 ms. Collision 
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energy (CE) was optimized and set at 31 eV for LAM and lamotrigine-13C3, d3 (ISTD). The 
precursor to product ion transition of m/z 256.01 → 108.98 (qualifier), 256.01 → 210.98 
(quantifier) for LAM and m/z 262.04 → 110.99 (qualifier), 262.04 → 217.01 (quantifier) for 
ISTD were used for parallel reaction monitoring (PRM). 
Data acquisition and processing were performed using Xcalibur™ and Quan Browser 
softwares (Thermo Fisher Scientific; Waltham, USA). 
Calculation of drug targeting efficiency 
Drug targeting efficiency (DTE) – relative exposure of the brain to the drug following 
intranasal administration vs. systemic administration – was calculated according to the 
following formula (Equation 7.): 
 
The value of DTE can range from −∞ to ∞, and the values higher than 1.0 indicate more 
efficient drug delivery to the brain following intranasal administration as compared to the 
systemic administration [105]. 
Calculations of the area under the time-concentration curve (AUC) and statistical analysis 
The calculation of area under the curve (AUC) of the time (min) – concentration (µg/L) 
curves of each group of animals were performed with the PKSolver add-in from Microsoft 
Excel (MS Office 2010) using the non-compartmental analysis of data after extravascular 
input (model #101) of LAM [106]. The AUC values were calculated using the linear 
trapezoidal method. Because of the incomplete elimination of LAM, the following parameters 
were not determined: λ, t1/2, AUC0-inf, AUMC0-inf, Vd, and Cl. All reported data are means ± 
SD. 
4.2.10. Stability measurements  
Stability tests of NPs were performed in Binder KBF 240 (Binder GmbH, Tuttlingen, 
Germany) equipment, with a constant-climate chamber. An electronically controlled 
APT.lineTM line preheating chamber and refrigerating system ensured temperature accuracy 
and reproducibility of the results in the temperature range between 10 and 70 °C and the 
relative humidity (RH) range between 10 and 80%. The stability test was performed at 25 ± 
2 °C with 50 ± 5% RH (room conditions). Sampling was carried out after 1 day; 3 and 6 
months. 
Statistical analysis was performed with TIBCO Statistica® 13.4 (Statsoft Hungary, Budapest, 
Hungary). All reported data are means ± SD. The Student’s t-test was used to determine the 
statistical significance. Changes were considered statistically significant at p < 0.05. 
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5. RESULTS AND DISCUSSION 
5.1. Development of NP formulation 
5.1.1. Knowledge space development and RA 
The first step was setting up an Ishikawa (fishbone) diagram including all the parameters 
influencing the desired NP product containing LAM as the active agent. The parameters were 
ranked into four groups (Figure 8.), namely, 1) material characteristics; 2) production method; 
3) product characteristics and 4) therapeutical expectations. This process gave a collection of 
preliminary knowledge and information, which helped to design the experiments and to select 
the appropriate CQAs and CPPs of the drug development procedure. 
 
Figure 8. Ishikawa diagram illustrating the parameters influencing the quality of the nanonized LAM 
containing NP product [82] 
First of all, the QTPP that describe the desired NP, which contain the nanosized LAM, were 
defined, and the CQAs and the CPPs were also identified. The results of the interdependence 
rating made by the research group members and the selected target and critical parameters are 
presented in the tables of Figure 9. Below them, Pareto charts can be seen, as the result of the 
RA generated by the software. The Pareto charts show the relative effect of the CQAs and the 
CPPs on the QTPP, namely, the numeric data of the critical factors and their ranking. In the 
diagrams, the same colors were used as in the tables; the factors that have minimal effect on 
the final product quality were marked with green, the factors with the medium effect were 
marked with yellow and the factors with great impact were marked with red. As a result, it 
was found that theoretically among the CQAs, the particle size and its distribution can be 
predicted to have the greatest effect on the quality of the targeted and desired NP product. The 
analog diagram shows that among the CPPs, milling time and speed had to be expected to 
have the highest influence on the quality of the aimed product (Figure 9.). According to the 
RA results, the studies of the practical development (screening studies and product 
preparation) were focused on the selected CQAs (particle size and distribution of LAM and 
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dissolution, as investigated outputs) and CPPs (milling time, milling speed and the API: 
additive ratio). 
 
Figure 9. Results of the interdependence ratings of the QTPP and CQA and of the CPP (upper parts) 
and the Pareto charts of the CQA and CPP with calculated numeric severity scores (lower parts) 
generated by the RA software [82] 
According to the results of the initial RA, the ratio of API and additives was found to be 
critical. In this meaning, in all additives, a ratio of 1:1 was selected for production; the milling 
time and milling speed were also constant, and the LAM size in the product, distribution, and 
dissolution as responses were investigated afterward. 
Preliminary experiments were carried out to collect information about the impact of grinding 
on raw materials (LAM and excipients) especially on micrometric properties and their 
structure. They were required because adhesion, aggregation, and amorphization may occur 
due to grinding. The raw materials were milled for 2 hours on 400 rpm. 
5.1.2. Investigation of NP formulations 
5.1.2.1. Micrometric properties 
Particle size analysis 
The particle size of the co-milled samples (Table 5.) was 10–25 μm, which is in the desired 
range. The particles are small enough to reach the nasal mucosa but not too small to be 
inhaled into the lungs. The smallest particle size was measured for the powder containing 
PVP and the largest one for the sample that contained PVA, particle size of which hardly 
decreased. In the table, it can also be seen that the particle size of LAM was between 120 and 
230 nm; it is in the target range. Compared to PM samples, it can be observed that in all three 
cases, the polymers could prevent the adhesion of the LAM particles, while the particle size of 
the polymers and LAM decreased due to co-milling, mostly in the samples that contained 
NaHA. 
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Table 5. The particle size of PM and co-milled (marked with R) samples 
 Length (µm) Width (µm) Average particle size of LAM (µm) 
PM_LAM_PVP 26.80 18.96 7.63 ± 20.07 
R_LAM_PVP 13.60 9.06 0.121 ± 0.027 
PM_LAM_PVA 26.90 17.05 13.88 ± 21.15 
R_LAM_PVA 25.33 16.61 0.15 ± 0.042 
PM_LAM_NaHA 37.07 18.75 26.17 ± 27.68 
R_LAM_NaHA 16.83 11.30 0.23 ± 0.016 
Particle size and morphology (SEM) 
Figure 10. shows the SEM pictures of the samples. It can be seen that LAM particles 
aggregated in the case of PM samples, which explains the large particle size. On the other 
hand, LAM particles adhered to the surface of the polymers and their size was in the nano 
range. In the case of the PVA-containing sample, uniformly dispersed, non-aggregated LAM 
particles can be observed as well. The increase in the temperature level due to grinding 
(30 °C–36 °C) was not high enough to reach the glass transition temperature of the polymers 
(PVP: 130 °C, PVA: 80 °C, NaHA: 244 °C); hence, as a result, no relevant change occurred. 
It can be concluded that the applied polymers offer great matrix to the LAM particles, where 
their individuality and stability, which have a great influence on the dissolution, are ensured. 
 
Figure 10. Particle morphology of PM and co-milled samples [82]. 
5.1.2.2. Structural investigations 
Generally, it can be said that the intensity of the peaks in XRPD diffractograms decreased in 
each co-milled sample due to the effect of milling and the presence of adjuvants, which 
indicates a reduced degree of crystallinity. In the product, which contained PVP and PVA, the 
nearly amorphous polymer covers the crystalline LAM; thus, the characteristic 2θ values are 
not visible on the chart compared to the PM. When the sample contained NaHA, the 
amorphous property of the polymer is more dominant; therefore, the characteristic peaks of 
the active substance are present; however, their intensity is not so high as in the case of the 
PM (Figure 11. A). 
On the DSC curves (Figure 11. B) of the sample which contained LAM and PVP, no 
endothermic peak can be detected because the particles merged into the polymer particles. In 
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the case of the NaHA containing product, the melting point was not significantly different 
from the one in the case of the PM, but the sample that contained PVA showed a significant 
decrease in melting point.  
 
Figure 11. XRPD diffractograms (A) and DSC curves (B) of co-milled (marked with R) and PM 
samples 
The crystallinity index values were calculated after the investigation of the DSC curves and 
the XRPD diffractograms to reveal changes in the degree of crystallinity in the milled samples 
compared to the PMs (Table 6.). It can be seen that the values are correlating, as similar 
results were obtained in both cases when the samples contained PVA or NaHA. In the case of 
the samples that contained PVP, the polymer-coated the LAM crystals and at the same time 
protected them from amorphization. That is why no peak can be seen in the DSC curve, but 
the crystallinity index increased based on the XRPD diffractograms. 
Table 6. Calculated crystallinity indexes of co-milled (marked with R) samples after DSC and XRPD 
measurements compared to PM samples 
 Xc (%) 
XRPD DSC 
R_LAM_PVA 67.42 74.45 
R_LAM_PVP 70.84 - 
R_LAM_NaHA 46.76 50.06 
5.1.2.3. Dissolution and permeability tests of the samples 
In the case of the in vitro (Figure 12.) investigations, it can be generally said that the co-
milled samples performed much better than the PMs. This means that higher dissolution 
(Figure 12. A) and permeability rates (Figure 12. B) were detected during the tests when 
LAM was co-milled with adjuvants. Especially the sample, which contained PVA, showed 
really high values as the percentage of dissolved LAM was 100% after 5 minutes and the 
highest LAM concentration in the acceptor phase was detected after 60 minutes. These results 
mean that the application of this formulation can lead to a rapid onset of action and sufficient 
LAM amount in the CNS, thus we used PVA as an adjuvant hereinafter.  
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Figure 12. Dissolution curves (A) and permeability profiles (B) of the PM and co-milled (R) samples 
Table 7. shows the calculated flux and permeability coefficient values. It can be seen that the 
values of PMs are lower than the values of the co-milled samples. The sample containing 
PVA had the best permeability as the highest concentration of LAM was detected in the 
acceptor phase after 60 minutes. The reason for this high permeability can be explained by the 
function of PVA, which can preserve the uniqueness of the particles, and the liberation of 
nanoparticles. The liberation increases the diffusion pressure due to the increased 
concentration gradient. In the case of PVA and NaHA, there was no considerable difference. 
Table 7. Calculated Flux and permeability values. Co-milled samples are marked with R. 
 J [µg/cm2/h] Kp [cm/h] 
PM_LAM_PVP 7.82 0.0026 
R-LAM_PVP 86.95 0.0261 
PM_LAM_PVA 9.56 0.0031 
R-LAM_PVA 100.00 0.0300 
PM_LAM_NaHA 13.47 0.0044 
R-LAM_NaHA 86.08 0.0259 
5.1.3. Definition and validation of the Design Space of the NP samples 
Our aim afterward was to identify the DS by optimizing the parameters of the dry milling 
method. The parameters were chosen according to previously discussed investigations. DS 
also allows to secure the quality of our samples and helps to find the optimal formulation for 
producing nasal powder formulation containing nanonized LAM particles. As the use of PVA 
was really promising, it was chosen as a hydrophilic matrix polymer to prevent the 
nanoparticles from aggregation [32]. 
Experimental plan and proven acceptable range (PAR) determination 
As it had been determined previously, there are 3 main CPPs (milling time and speed, 
LAM:PVA ratio). The software recommended a 33 factorial experimental plan. The PAR, 
which was generated by the MODDE 11.1 software, is ‘a characterized range of a process 
parameter for which operation within this range, while keeping other parameters constant, 
will result in producing a material meeting relevant quality criteria’, according to the ICH Q8 
guideline. Table 8. shows the factors and their variation levels along with the chosen 
responses and their values, and also indicates the PAR of all responses. 
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Table 8. The parameters of milling, the chosen responses, and their values 
Name Settings  Name Min Max Target 
Milling time (h)- X1 0.5, 1, 2  Mean size of LAM -Y1  250 nm 350 nm 
Milling speed (rpm)- 
X2 
200, 300, 400 
 
Standard Deviation -Y2  ±100 nm ±200 nm 
PVA:LAM (m/m%)- 
X3 
0.5, 0.75, 1 
 Released LAM % after 5 
mins -Y3 
70%  85% 
  
 Released LAM % after 10 
mins -Y4 
85%  100% 
DoE analysis, summary of fit 
It can be observed that the high milling time, speed and LAM:PVA ratio do not always result 
in small particle size and standard deviation, and high dissolved amount of LAM. To check 
the validity of the experimental design, the following statistical parameters were determined: 
R2, Q2, model validity, and reproducibility. The values of these parameters are presented in 
Table 8. All responses were fitted and well predicted by the model as R2 values were at least 
0.8 and all the Q2 values were above 0.5. The validity value of the models was above 0.25 in 
each case, which indicates a good model. The reproducibility values also presume that the 
process is well-reproducible as they were above 0.9. Model significance test using ANOVA 
generated lower 0.05 p values for all responses. Also, there was no lack of fit detected, as the 
model error was not significantly different from the replicate error (p> 0.05) (Table 9.). 
Table 9. Summary of fit for DoE, ANOVA Test results for model significance and lack of fit (p 
values) 
Response R
2
 Q
2
 Validity Reproducibility Model Significance Lack of fit test 
Y1 0.82 0.64 0.34 0.96 5.57E-06 0.073 
Y2 0.88 0.72 0.28 0.97 8.19E-07 0.057 
Y3 0.80 0.70 0.49 0.94 4.82E-08 0.285 
Y4 0.87 0.77 0.69 0.91 1.15E-08 0.115 
Effect of the milling parameters on the responses 
After the evaluation of the coefficient plots (Figure 13.), it can be seen that milling time and 
speed have an effect on Y1. As the milling time and speed increase, the particle size of the 
API decreases, so it can be concluded that these parameters influence mostly Y1 and Y2. The 
values of LAM size were between 172 nm and 7015 nm. There were some samples, where 
due to the inappropriate parameters the particles aggregated, which means that the detection 
of unique particles was not possible. The same phenomenon was observed in the case of Y2. 
The increasing milling time and speed decreased Y2. This is related to the smaller particle 
size because the particles became more unique (no aggregation occurred), so the particle size 
determination was simpler above certain parameter values. In the coefficient plot of SD, a 
significant interaction could be observed, but its interpretation is possible after the 
examination of the surface plots. The Y3 and Y4 values increased due to the increased values 
of the milling parameters. The reason for this tendency is that the small particles can leave the 
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matrix easier than bigger ones, and also due to reduced particle size, the bigger surface is 
advantageous if the aim is rapid dissolution. However, in these cases, the PVA:LAM ratio has 
an effect on the dissolution rate due to the matrix effect of the polymer. A quadratic term 
between milling time is also observed in the coefficient plots. 
 
Figure 13. The scaled and centered coefficient plots of the responses, where X1: milling time; X2: 
milling speed; X3: PVA: LAM (m/m%) ratio (X3) [83] 
Design Space estimation 
The major objectives of QbD are risk minimization and DS development for the product. 
Design Space plots are generated by superimposing several contour plots and combining it 
with probability analysis [96,98,100]. Considering the models developed for the CQAs, 
Monte Carlo simulations were used to estimate the probability to meet the product 
specifications in the design region. The plot is a color-coded region and contour lines, which 
have the role to separate the design region according to the probability of failure, are 
expressed in percentage (%) of failure. The green region, with a low probability of failure, is 
named the DS. The edges of the hypercube illustrate the generated PAR. The milling time was 
between 1.4 h and 1.7 h, while the PVA:LAM ratio was between 0.77 and 0.83. The milling 
speed was kept constantly high, on 400 rpm as it had the narrowest variation range among the 
input variables, and it had the highest influence on the responses according to the coefficient 
plots. The target values can be achieved using parameters in these ranges that are near to 0 
levels in Table 8. MODDE can calculate a setpoint after running the optimizer that can 
estimate the tolerance available for the factors. During the setpoint analysis, a robustness 
estimate is calculated by adding disturbances to the factors around the setpoint. In our study, 
it was also our aim to find a robust setpoint. It is a solution with maximum factor ranges that 
will predict results inside the specifications. The robust setpoint is the center of the green 
region which is 1.5 h milling time with 0.8 PVA:LAM ratio on 400 rpm speed (Figure 14.) in 
our case. 
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Figure 14. The Design Space of the dry milling method. The edges of the hypercube are between 
1.4 h and 1.7 h in the case of milling time, 0.77 and 0.83 in the case of the PVA: LAM ratio, 
respectively. Milling speed is kept constantly 400 rpm. The parameters of the robust setpoint are 1.5 h, 
400 rpm, and 0.8 PVA:LAM ratio [83] 
Validation of the Design Space 
As there are infinite good formulations, it seemed to be the most rational to keep the 
PVA:LAM ratio at the robust setpoint. Milling speed was kept at 400 rpm because the interval 
was narrow and lower speeds were not adequate. In our previous study, the milling time was 2 
hours, but we aimed to rationalize the processing time. After the evaluation of the results of 
nanoLAMpowder – that was prepared according to the robust setpoint and the results which 
had been proven to be good – it would have been irrational to use longer milling times. That 
is why milling time was no longer than 1.5 hours. The regions of the DS were expressed in % 
of failure, the validation process of the DS based on these regions. The first sample was 
prepared outside the 50% probability of failure (P1), the second was in the region of 50% 
probability of failure (P2), the third was in the near edge of 10% probability of failure (P3), 
the fourth was in the region of 5% probability of failure (P4), the fifth was in the near edge of 
1% probability of failure (P5), the sixth was inside the region of 0.5% probability of failure 
(P6), and the last one was prepared according to the robust setpoint (P7- nanoLAMpowder). 
Validation samples were prepared with PVA:LAM ratio of 0.8 on 400 rpm and by using 
different milling times, that was varied according to Table 10. 
Table 10. The experimental plan of Design Space validation 
Sample Milling time (h) Milling speed (rpm) PVA: LAM ratio (%) 
Powder 1 (P1) 0.6 
400 0.8 
Powder 2 (P2) 0.9 
Powder 3 (P3) 1.0 
Powder 4 (P4) 1.1 
Powder 5 (P5) 1.2 
Powder 6 (P6) 1.3 
Powder 7 (P7) -
nanoLAMpowder 
1.5 
Particle size and morphology 
After the particle size determination (Table 11.), the following comments can be made: long 
milling time causes smaller mean particle size and standard deviation. This can be explained 
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by the non-aggregated property of the LAM particles due to the milling. P7 sample showed 
the best values in this case too with a very small average particle size of LAM (97.46 nm). 
This small particle size, the homogenous distribution and the uniqueness of the LAM particles 
cause the API to leave the surface of the polymer easier. This property resulted in the best 
dissolution rate (97.32±4.95% released LAM after 10 mins) among the tested samples. The 
only sample that did not correspond with the criteria (the target particle size of LAM was 250 
nm) was P1, which can be explained by the short milling time. In the SEM picture of the 
sample, heterogeneous distribution, large-sized particles, and adhesion can be seen, which 
may lead to good dissolution, but due to these properties and high standard deviation, the 
reproducibility of the sample and these results are quite uncertain. 
Table 11. The results of particle size analysis 
Sample Y1- Mean size of LAM (nm) Y2- Standard Deviation (± nm) 
Powder 1 (P1) 521.42 310 
Powder 2 (P2) 212.77 150 
Powder 3 (P3) 198.71 120 
Powder 4 (P4) 143.36 80 
Powder 5 (P5) 124.18 60 
Powder 6 (P6) 140.62 70 
Powder 7 (nanoLAMpowder) 97.46 60 
In vitro dissolution test 
The results of the in vitro dissolution test can be seen in Table 12. They show that the highest 
amount of LAM was dissolved from the sample that was prepared according to the robust 
setpoint. 80.48% of the API dissolved from the sample after 5 min and 97.32% after 10 min, 
respectively. It means that only this formulation fulfilled the predefined target response values 
(<85% dissolved LAM after 5 min, 100% dissolved LAM after 10 min). The rest of the 
formulations performed also well during the test, but except for nanoLAMpowder, just two 
formulations (P1, P4) responded to the predetermined criteria of this test. An explanation of 
the unexpected good dissolution results in the case of P1 can be that there are small particles 
that can leave the polymer matrix easily as well as the aggregated particles can disaggregate 
easily. However, these mechanisms cannot be controlled, which will lead to uncertain 
reproducibility as it was mentioned above. 
Table 12. The result of the in vitro dissolution rate study 
Sample 
Y3- Dissolved amount of LAM 
after 5 minutes (%) 
Y4- Dissolved amount of 
LAM after 10 minutes (%) 
Powder 1 (P1) 71.24 87.47 
Powder 2 (P2) 61.06 73.78 
Powder 3 (P3) 64.67 73.27 
Powder 4 (P4) 77.04 89.52 
Powder 5 (P5) 66.20 72.03 
Powder 6 (P6) 63.69 76.63 
Powder 7 (nanoLAMpowder) 80.48 97.32 
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5.1.4. In vivo studies 
The nanoLAMpowder formulation was compared to the PM and IV injection. In the case of 
IV and intranasal administration, the concentration values of LAM in the blood plasma vs. 
time profiles are shown in Figure 15. Compared to the nasal formulations, the plasma 
concentration of LAM was significantly higher in the IV group (2.38 ± 0.14 mg/L) in the first 
3 min which provided the highest measured plasma concentration after the initiation of the 
injection. There were significant differences between the plasma concentrations in the case of 
nasal powder forms only in the first 3 min after application, however, these values were 
negligible compared to the IV administration. This means that there was no considerable 
difference in the absorption of the API into the systemic circulation by intranasal 
formulations. 
The AUC corresponds to the amount of drug absorbed into the systemic circulation during the 
investigated period. There were no remarkable differences between the plasma AUC values of 
powders (PM: 8.59±1.35 µg/mL*min; nano LAM powder: 13.63±1.95 µg/mL*min), 
however, they were significantly lower than the AUC values of IV administration 
(118.35 µg/mL*min) (Figure 15.). This could be explained with the 100% bioavailability of 
the drug after IV application, which can be achieved only in the case of intravascular 
administration. 
 
Figure 15. The concentration and AUC values of LAM in the blood plasma in case of IV and 
intranasal administration. 
The concentration values of LAM in the brain samples are shown in Figure 16. The 
application of nanoLAMpowder sample resulted in a significantly higher drug concentration 
(2.16 ± 0.21 µg/brain g) in brain tissues compared to the PM (0.18 ± 0.76 µg/ brain g). The 
transport of the drug could be assumed by both intranasal formulations, because the drug was 
presented in the brain 3 min after administration, which period was not enough for the API to 
pass through the BBB after absorption into the systemic circulation from the nasal mucosa. In 
the case of PM, the drug-level in the brain was increased 40 min after application, which 
could be explained by the slower dissolution of microsized LAM particles and with the drug 
absorption through the BBB from the blood plasma. 
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In terms of cerebral AUC values of the formulations (Figure 16.), the administration of IV 
injection resulted in a higher AUC value (253.60 ± 7.66 μg/brain g*min) compared to the 
nasal formulations. This phenomenon could be elucidated with the 100% presence of the drug 
in the blood plasma after IV application, which may be absorbed through the BBB to target 
the brain. Due to the quick dissolution of nanoparticles, a higher amount of LAM could reach 
the brain directly by axonal transport in the case of nanoLAMpowder (69.05 ± 10.08 μg/ brain 
g*min), resulting higher AUC values than with the usage of PM (54.01 ± 15.39 μg/brain 
g*min). 
 
Figure 16. The concentration and AUC values of LAM in the brain samples. 
To determine the utilization of the drug in the brain tissue, the absolute bioavailability was 
calculated, where the brain AUC – resulted by IV injection – was considered as 100% (Table 
13.). In the case of nanoLAMpowder, the absolute bioavailability of LAM was 39.84%, while 
in the case of PM it was only approximately 21%. 
The cerebral drug targeting efficiency index (DTE) reflects the relative accumulation of the 
drug in the brain following intranasal administration as compared to systemic administration. 
DTE data were above 1.0 in case of both nasal powders, as the LAM could reach the brain 
tissues more efficiently via axonal transport, than through the systemic circulation. This 
resulted in remarkable absorption through the nasal mucosa directly into the CNS and 
parallelly resulted in poor transepithelial absorption into the systemic circulation. 
Table 13. Calculated parameters of intranasal powders applying IV administration as a benchmark. 
 abs. BA for the brain (%) AUCbrain/AUCblood DTE  
IV injection 100 2.02 1 
nano LAM powder 39.84 5.06 2.49 
PM 21.30 6.29 3.11 
5.1.5. Stability study of the nanoLAMpowder 
In the tested period, the key properties related to the powder formulation did not change 
considerably. The results of particle size determination resulted in same particle size of the 
product during the examined period (Table 14.), which shows that the product's particles did 
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not aggregate. The size falls into the range which is desired in the case of nasal powders, 
which is 10-40 µm. 
Table 14. The results of particle size investigation the product. In the table n.s means that there is no 
significant difference at 95% level. 
 Average size of the product (µm) t-value p-value Significance 
1-day 29.91±15.85 -0.1435 0.8883 n.s. 
3 months 28.48±12.81 0.2994 0.7690 n.s. 
6 months 26.52±11.14 0.9064 0.3801 n.s. 
The particle size of LAM in the formulation showed an increase with relatively high standard 
deviation (Table 15.). However, according to results of the statistical analysis there is no 
significant difference in the particle sizes during the storage period, thus the previously 
experienced rapid and high degree of release was predicted. 
Table 15. The results of particle size investigation of LAM. In the table n.s means that there is no 
significant difference at 95% level. 
 Average size of LAM (nm) t-value p-value Significance 
1-day 97±60 1.2382 0.2347 n.s. 
3 months 105±77 0.7934 0.4408 n.s. 
6 months 120± 84 -0.0408 0.9687 n.s. 
The results of the structural investigatios (DSC and XRPD) confirmed that the LAM 
remained partly amorphous in the tested period. Moreover, according to the results of in vitro 
dissolution tests the rapid release of LAM was maintained during the examined period. 
5.2.  Development of NC formulations 
5.2.1. Identification of factors affecting product quality 
The first step before the experiment was to identify and systematize the most influencing 
factors that could affect product quality. This scheme allowed us to design our research plan 
more effectively, optimizing costs and time. In the Ishikawa-diagram of the NC product, we 
could identify 4 main groups of influencing factors (Figure 17.): material characteristics, 
production method, investigation methods and, therapeutical and regulatory expectations. 
Among these factors, the type and amount of surfactant, liquid lipid, surface modifier, coating 
material and cryoprotectant, the amount of API and the particle size, its PDI and the surface 
characteristics (ZP) of the NCs have the greatest impact on the quality of the product. The rest 
of the factors were not found to be as influencing during the preformulation tests and the 
literature review. After setting up the Ishikawa-diagram we decided to set up a factorial 
experimental plan, where the type of the coating material and the liquid lipid was varied. The 
experiments were optimized for particle size and PDI. 
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Figure 17. Ishikawa-diagram of the NC product 
5.2.2. Particle size, particle size distribution and surface charge characterization of NCs 
As a first step, the particle size and surface charge of the NCs were analyzed (Table 16.). The 
NCs were always in the 290-380 nm range that is acceptable according to the FDA regulatory, 
as the particle size of nanosystems has to be between 100-1000 nm [107]. Our aim was to 
develop NCs that were in the lower part of this range and showed a homogenous particle size 
population (PDI <0.2). These requirements were fulfilled for the NCs only if the liquid 
lipid:surfactant ratio was 1:1. LAM incorporation resulted in a significant increase in particle 
size as compared to blank NCs. In all cases, zeta potential values were similar, positive and 
close to zero that may be advantageous for mucoadhesion and mucodiffusion [108]. In the 
other samples, the particle size and PDI did not meet the criteria that we had set previously, 
and the particles were not in the nano range, so in the following the most promising sample 
was tested. The freeze-dried formulation showed some increase in particle size and PDI after 
redispersion (504 ± 3 nm, 0.538 PDI), indicating some aggregation, that could happen due to 
the presence of mannitol. However, this aggregation was not observed on the freeze-dried 
state when the powder cake was analyzed with imaging technology as the particle size 
showed 179 ± 62 nm. This means that the NCs maintained their size after freeze-drying. 
Another relevant observation was an increase in zeta potential in the NCs resuspended after 
freeze-drying, which can be explained by the presence of the cryoprotectant. The 26.5 ± 0.9 
value means that the NCs may have high degrees of stability.  
Table 16. Results of the particle size and surface characterization of the NCs. 
 Z-average (d. nm) PDI 
Zeta potential 
(mV) 
Blank NCs after centrifugation (2:1 ratio) 2815 ± 159 0.795 0.99 ± 0.4 
LAM NCs after centrifugation (2:1 ratio) 1210 ± 68 0.773 1.3 ± 0.1 
Blank NCs after centrifugation (1:2 ratio) 1477 ± 72 0.643 0.80 ± 0.3 
LAM NCs after centrifugation (1:2 ratio) 1399 ± 59 0.950 0.94 ± 0.5 
Blank NCs after centrifugation (1:1 ratio) 294 ± 9 0.175 0.39 ± 0.2 
LAM NCs after centrifugation (1:1 ratio) 305 ± 7 0.188 1.0 ± 0.3 
FDNCs 
Freeze-dried: 179 ± 62 
After redispergation: 504 
± 3 
0.538 26.5 ± 0.9 
37 
5.2.3. Encapsulation efficacy (EE) and drug loading (DL) 
The EE of LAM was 58.44% ± 4.81 in the NCs and the DL was 5.31% ± 0.67. This is an 
acceptable level of EE for a nanoformulation, particularly since it was achieved with a very 
high drug loading. 
5.2.4. Particle morphology 
We analyzed LAM-loaded FDNCs (Figure 18. A) and freeze-dried NCs (Figure 18. B) by 
SEM. The core and shell substructures of the NCs were clearly visible before freeze-drying. 
In both cases, NCs presented a spherical shape and homogenous distribution. There was no 
sign of non-encapsulated, crystalline LAM around the NCs and there was no sign of 
aggregation in the mannitol matrix, so the pictures indicated good particle stability and no 
warnings regarding drug aggregation. 
 
Figure 18. The morphology of LAM loaded NCs (Picture A.) and FDNCs (Picture B.) 
5.2.5. In vitro drug release and permeability studies 
The in vitro release study showed faster release of LAM in the case of both NCs formulations 
compared to pure LAM powder (Figure 19. A). It was detected that more than 20% of LAM 
released after 5 min and ~60 % LAM after 15 min; afterward, a drug release plateau was 
observed. The FDNCs released the drug slower than NCs but markedly faster than the drug 
powder. In this case, ~40% LAM was released after 10 min, and 50% after 15 min, a point 
where the release started to level-off. At 15 min, both NCs formulations released between 2.5 
and 3-fold more LAM than the drug powder. For nasal administration, the first four points are 
the most important, because the mucociliary clearance renews the nasal mucus approximately 
every 15 min, thus limiting the API residence time at this site. In this sense, the fast release of 
LAM from the nanoformulations can be considered an advantageous characteristic for nasal 
delivery. Moreover, the use of chitosan may extend the residence time, which means that the 
formulation could have enough time to get into the CNS. 
Next, we performed a permeability study to compare how the different formulations could 
modify the capacity of LAM for crossing biological barriers (Figure 19. B). In the case of 
nasal administration, it is important to achieve a high permeability rate through the mucosa, 
which means that the API reaches its target more efficiently. NCs and FDNCs formulations 
performed similarly well in this experiment, and much better than a LAM powder, which 
achieved the lowest amount of permeated drug. In the case of the NCs formulations, 
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~25 µg/cm2 LAM diffused through the membrane, which is 2.5 times higher than the amount 
of drug diffused from the raw powder formulation. This was a remarkably high amount if we 
take into consideration that an average human nasal mucosa is around 150-200 cm2 [26]. 
 
Figure 19. In vitro drug release (A) and permeability (B) studies of different NCs formulations and 
LAM powder 
Tha calculated Flux (J) and permeability coefficient (Kp) values (Table 17.). The Flux shows 
how much API can diffuse through the membrane per hour and the surface unit, while Kp is 
the Flux-donor phase ratio. The results of the table show that the LAM could diffuse in higher 
amounts through the membrane to the acceptor phase from the NC formulations than from the 
powder and that there was no significant difference between both nanoformulations. These 
results validated the previous observations on drug diffusion, as the NC formulations showed 
higher values for these parameters than the powder. 
Table 17. Calculated Flux (J) and permeability coefficient (Kp) values for the different LAM 
formulations 
 J (µg/cm2/h) Kp(cm/h) 
LAM 31.48 0.021 
NCs 41.29 0.023 
FDNCs 42.96 0.03 
5.2.6. In vivo drug release study 
In a final step, we performed the in vivo administration of the LAM formulations and we 
performed PK analysis both in the blood and brain (Figure 20. and 21., respectively). The 
plasma concentration of LAM was significantly higher for the NCs group than for the FDNCs 
group, and this was particularly remarkable in the 3 min datapoint: 0.18 ± 0.03 µg/mL vs. 
0.01 ± 0.002 µg/mL LAM concentration for NCs and FDNCs, respectively. This could be 
explained by the fact that the API reached the systemic circulation without passing through 
the liver. Another possible explanation of the relatively high absorption of liquid NCs is that 
the liquid could spread over a larger surface that caused higher plasma concentrations. 
Moreover, another possible explanation of the poor permeation of the FDNCs is that in the 
nasal cavity the amount of water is limited. As the solid particles need to be solubilized before 
permeation, this limited amount of water can retard or even limit the extent of the absorption. 
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The ratio of AUC values shows that the API from the liquid NCs reached the plasma 12.28-
fold more than the API in freeze-dried NCs (AUC(NCs)=6.13 ± 0.52 min*µg/mL plasma; 
AUC(FDNCs)= 0.50 ± 0.16 min*µg/mL), but they were well below the IV formulation (125.08 
± 17.46 min*µg/mL). 
 
Figure 20. The concentration values and AUC of LAM in the blood plasma. 
Nasal administration of LAM in NCs achieved higher brain drug concentrations than FDNCs. 
Indeed, NCs resulted in significantly higher AUC values (11.65 ± 1.03 min*µg/g) than 
FDNCs (2.06 ± 1.10 min*µg/g), while the AUC value of IV administration was 250.603 ± 
7.66 min*µg/brain g. The ratio of AUC values between the liquid and the solid NCs was 5.65, 
which means that this formulation could provide better drug absorption. In any case, LAM 
was present in the CNS shortly after administration since it was detected there even at the 3 
min extraction point. This time seems too short for LAM to be absorbed and to cross through 
the BBB, which indicates a possible axonal transport of the drug. Besides, in the case of 
FDNCs, the drug would take more time to be absorbed into the systemic circulation (Figure 
21.) through the nasal mucosa, but it is still detected in the CNS. FDNCs showed very 
constant LAM levels in the CNS after the first 10 min, and we hypothesize that this could be 
due to the presence of parallel transport mechanism of axonal transport and access through the 
BBB.   
 
Figure 21. The concentration and AUC values of LAM in the brain samples. 
Table 18. represents the calculated values of the investigation. The brain: plasma ratios of the 
NCs and FDNCs were 1.90, and 4.13, respectively. This means that the API was more 
concentrated in the CNS than in blood plasma. The fact that this value is higher for the 
FDNCs than for the NCs indicates that this concentration ratio is not only dependent on drug 
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biodistribution, but rather on other biopharmaceutical processes. We think that this higher 
ratio achieved with FDNCs could indicate a higher contribution of direct axonal drug 
transport for this formulation as compared to NCs.  
The cerebral drug targeting efficiency index (DTE) reflects the relative accumulation of the 
drug in the brain following intranasal administration as compared to systemic administration. 
DTE data was around 1.0 in the case of NCs, which means that LAM presented in similar 
concentrations in plasma and brain tissues, respectively. As for the FDNCs, the LAM could 
reach the brain tissues two times more efficiently via axonal transport, than through the 
systemic circulation, which is indicated by the value above 2.0. This resulted in remarkable 
absorption through the nasal mucosa directly into the CNS and parallelly resulted in poor 
transepithelial absorption into the systemic circulation in case of the solid-state sample. 
Table 18. Calculated parameters of intranasal powders applying IV administration as a benchmark. 
 AUCbrain/AUCblood DTE 
IV injection 2.02 1 
NCs 1.90 0.94 
FDNCs 4.13 2.04 
5.3. Comparison of NP and NC formulations based on their in vivo performance 
Table 19. summarizes the main in vivo properties of the samples. It can be seen that the 
nanoLAMpowder had the greatest presence in the brain tissues and also in the plasma. 
Generally, compared to the NP samples, the NC formulations showed smaller AUC values. 
Moreover, the targeting of LAM into the CNS was much better in the case of NPs which can 
be seen from AUCbrain/AUCblood data. The DTE values of NPs were also higher compared to 
the NCs, which means that LAM could reach its site of effect more efficiently when 
administered in powder formulation. The differences can be explained by the administered 
dose which is much higher in the case of NPs because the drug loading capacity of NCs is 
limited. Accordingly, the application of NP formulations can be advantageous because of the 
higher dose that can be administered into the nostril.  
Table 19. Calculated parameters of the formulations. 
 AUCbrain (min*µg/ g) AUCblood(min*µg/mL) AUCbrain/AUCblood DTE 
PM 54.01±15.39 8.59±1.35 6.29  3.11 
nanoLAMpowder 69.05±10.08 13.63±1.95 5.06  2.49 
NCs 11.65±1.02 6.13±0.52 1.90 0.94 
FDNCs 2.06±1.10 0.50±0.16 4.13 2.04 
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6. CONCLUSION 
To summarize the thesis, the following statements can be made according to the aims: 
I. After the literature review, it was found that the combination of nasal drug delivery, 
nanosystems and QbD methodology can be advantageous to develop innovative and improved 
bioavailability products for LAM. The development of alternative dosage forms for LAM is 
important because it was found in the literature that on the market, only tablets, disintegrating 
tablets, and chewable tablets can be found, which can be ineffective in some cases, such as in 
malabsorption or acute diarrhea. It was also found that there is great potential –despite the 
poor number of marketed products- in the research and development of NPs, because they 
have many advantageous properties compared to liquid formulations. Moreover, the 
development of NCs can eliminate some possible drawbacks of nasal delivery according to 
the current information found in the literature. 
II. The quality influencing factors were collected with the help of an Ishikawa diagram. The 
results of the RA showed that amongst the CQAs, the particle size, its distribution and the 
dissolution rate of LAM, while amongst the CPPs the LAM:additive ratio, the milling time 
and speed are the most critical factors of NP production. After the preliminary studies, based 
on the results of the particle size analysis, in vitro release and permeability tests, PVA was 
chosen to serve as a matrix for nanosized LAM particles. The optimization of the dry milling 
process was executed with DoE, which meant the Design Space determination and validation 
of the powder production. Due to the DS estimation, a more economical – time- and material-
effective – sample preparation method was set up and the results of nanoLAMpowder (milling 
time: 1.5 h, milling speed: 400 rpm, PVA:LAM ratio: 0.8) were in the aimed ranges. The 
results of the in vitro dissolution test showed the highest amount of released LAM from 
nanoLAMpowder during the validation process. 
III. NanoLAMpowder was tested in further investigations and was compared to its PM. The 
micrometric investigations showed that the LAM was in the nano range (97 ± 60 nm) in the 
case of nanoLAMpowder, while it was aggregated in the PM sample. The results of the in 
vitro dissolution and permeability tests showed a rapid and high release from the 
nanoLAMpowder. The in vivo investigation showed that the plasma concentration of LAM 
was significantly higher in the IV group during the test compared to the nasally administered 
samples, among which there was no considerable difference. However, the application of 
nano LAM containing sample resulted in a significantly higher drug concentration in the brain 
tissues compared to the PM. Also, the presence of LAM in the CNS was higher in the case of 
nanoLAMpowder according to the AUC values. The axonal transport of the drug was 
assumable by both intranasal formulations. The results of the stability studies showed that the 
key properties (particle size, crystallinity properties, in vitro release profile) of the NP did not 
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change significantly, so the efficiency presumably maintained during the tested period. 
According to our aims, we were able to develop an inline, modified diffusion method, which 
is a more accurate, easy-to-implement, more informative method that has made our 
measurements more simple and more efficient. 
IV. Then, the aim was to develop and investigate novel, LAM containing core-shell NCs. The 
identification and prioritization of most influencing factors were collected with the help of an 
Ishikawa diagram.  The components of the NC formulation were determined. According to 
the results of the preliminary experiments and size optimization, chitosan-coated NCs with 
LAM were formulated both as a liquid suspension and as a freeze-dried powder.  
V. The following step was the optimization of the main influencing factors of production. 
Accordingly, the parameters of freeze-drying were set and the most promising cryoprotectant 
(mannitol) was determined. Then, during the investigation procedure, the particle size of 
LAM NCs was under 500 nm, the zeta potential was nearly neutral in the case of NCs, while 
they turned out to be positive in the case of FDNCs. LAM released quickly from both NC 
formulations, with 50% payload released after 15 min. The permeation rate of LAM was also 
higher for the NC samples than for LAM in powder form. In vivo studies showed that LAM 
could reach the brain in significant amounts, particularly in the case of NCs. The kinetics and 
biodistribution ratio of the drug between brain and plasma suggest that there is axonal 
transport involved in drug absorption, which means that the LAM can reach its site of action 
in an amount sufficient for effect. 
VI. In the living body, nanosystems could be more effective due to the fact that their smaller 
particle size leads to a larger specific surface, which usually results in higher dissolution rate 
and increased adhesion to mucous membranes. Powder formulations, when administered 
through the nose, can withdraw water. This could be advantageous because the tight junctions 
are widened thanks to which the API can pass easier through the membrane and, at the same 
time, the formulation becomes a bit viscous, which may increase its residence time on the 
mucosa. In the case of nanoLAMpowder, PVA was used as a mucoadhesive, wetting agent, 
which provided a great matrix for LAM nanoparticles. Due to the presence of PVA, the co-
milling was more effective, and the small particles could leave the water-soluble matrix 
easily, which resulted in a great in vitro and in vivo performance. As for the NCs, chitosan 
was served as a shell component for the nanoparticles. This coating material can extend the 
residence time on the nasal mucosa and can improve the adhesion to the mucosa, which 
resulted in great API presence in the CNS in our case. However, according to the in vivo 
results of the NP and NC formulations, it can be concluded that the presence of LAM in CNS 
was significantly higher in the case of NPs and also, the targeting of LAM was better. In the 
case of NCs, it is not possible to encapsulate large amounts of API into the capsules, which 
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results in lower administration doses. As for NPs, the administration dose is much higher, 
which in our case, resulted in better in vivo performance. Therefore, and because of the much 
more simple, economical and ecological sample production method, in our opinion, the NPs 
could provide a great, short-term alternative for the marketed tablets in the therapy of 
epilepsy, if their application is not possible. 
New findings of the work: 
 As there is a limited number of nasal powder products on the market, the availability of 
information about them is poor despite, there is a great potential in their application. Their 
stability is better, the administration dose is higher compared to the liquid formulation, the 
residence time on mucosal surfaces is longer, fewer additives are needed during the 
formulation process. Also, these systems are special because their design, development, and 
optimization should be parallel with those of the delivery device to assure proper dosing. 
Thus, the thesis provides up-to-date and summarized knowledge about NPs. 
 The determination of QTPP of nasal powder products and the collection of the most 
influencing CQAs (particle size, particle distribution and dissolution rate of LAM) and CPPs 
(milling time, milling speed, API: additive ratio). The dry milling sample production method 
was validated. Accordingly, a novel, partially amorphous, nanosized LAM containing, brain 
targeted NP was developed, which could provide an alternative for tablets when their 
administration is not possible. The formulation is necessary because there are no other LAM 
containing dosage forms on the market, just tablets. The LAM could release from the 
formulation rapidly and in a high amount.  
 Adaptation, development and validation of a permeability investigation method. The 
modified diffusion model is suitable for inline, real-time detection, adapted to nasal 
conditions, using small volumes of phases, appropriately impregnated membrane, to monitor 
the diffusion of the drug, and to determine its concentration in the acceptor and donor phases. 
Accordingly, we have succeeded in developing an easy-to-implement, easy-to-reproduce, 
accurate, informative and time-efficient method. 
 The development of a LAM containing, nanostructured NC formulation for nasal 
administration. Optimized technological protocol to prepare an intermediate sample 
containing NC. The formulation can be administered in liquid and solid forms. The NC 
formulation can offer a great alternative for LAM administration into the CNS in a 
considerably high amount. Using this kind of nanoformulation, the advantages of 
nanosystems and nasal delivery can be combined. 
 The developed formulations can be suitable-especially the NP formulation- for application 
in the therapy of epilepsy for a short time instead of tablets, for example in GI malabsorption 
or acute diarrhea, after further investigations. 
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